Advances in Targeting HER3 as an Anticancer Therapy

• Type of Material: Article
• Authors: Ning Jiang, Emory University; Nabil F Saba, Emory University; Georgia Chen, Emory University
• Language: English
• Date: 2012-10-10
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2012 Ning Jiang et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://www.hindawi.com/journals/chrp/2012/817304/
• Title of Journal or Parent Work: Chemotherapy Research and Practice
• ISSN: 2090-2107
• Volume: 2012
• Issue: 2012
• Start Page: 1
• End Page: 9
• Research Categories: Health Sciences, Oncology

Abstract

HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications.